Regeneron Doubles Guidance for Eylea After Strong Launch
Regeneron revised its earnings guidance for Eylea (aflibercept) for 2012, from $140 million to $160 million to a range of $250 million to $300 million, after the newly launched therapy for wet age-related macular degeneration had a strong performance in its first quarter of sales. The Tarrytown, N.Y.-based firm reported that 30,000 injections of Eylea had been given to date.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST